Notice of Special Interest (NOSI): Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)Notice Number: NOT-AI-20-031
In order to rapidly improve our understanding and available control measures for SARS-CoV-2 and COVID-19, NIAID is encouraging the submission of applications to address the following research areas of interest:
- Studies to identify optimal in vitroculture requirements and conditions;
- Development of reagents and assays for virus characterization;
- Studies to understand critical aspects of viral infection, replication, pathogenesis, and transmission;
- Studies to identify viral epitopes critical for binding neutralization;
- Studies to examine virus stability and persistence;
- Production of molecular clones of SARS-CoV-2, reporter viruses and recombinant viral proteins;
- Development of animal models of SARS-CoV-2 infection suitable for screening vaccine and therapeutic candidates and/or pathogenesis studies;
- Studies on the evolution and emergence of SARS-CoV-2 viruses including the identification of factors that affect viral host-range and virulence;
- Virologic and serologic surveillance studies of the distribution and natural history of SARS-CoV-2 viruses in animal populations and in humans at the human/animal interface with particular emphasis on host reservoirs and understanding cross-species transmission events;
- Development of sensitive, specific, and rapid clinical diagnostic tests for SARS-CoV-2;
- Development of SARS-COV-2 therapeutic candidates; broad-spectrum therapeutics against multiple coronavirus strains; examination of SARS-CoV-2 antiviral activity of existing or candidate therapeutics initially developed for other indications;
- Identification and evaluation of the innate, cellular and humoral immune responses to SARS-CoV-2 infection and/or candidate vaccines, including, but not limited to: cross-reactive antibodies from individuals exposed to SARS-CoV-2 and other coronaviruses; viral epitopes critical for antibody binding and neutralization; immune-mediated pathology or host factors that might predispose to severe infection; and
- Development of SARS-CoV-2 vaccine candidates that include emerging antigen design strategies, novel platforms or delivery approaches, adjuvants, or assessing cross-neutralization potential of SARS-CoV vaccine candidates.
This notice applies to due dates on or after April 5, 2020 and subsequent receipt dates through April 5, 2021.
Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcement through the expiration date of this notice:
PA-19-052 NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
PA-19-053 – NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
PA-18-591: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp – Clinical Trial Optional)
PA-19-056 NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
PA-19-272 – PHS 2019-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
PA-19-270 – PHS 2019-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
National Institute of Drug Abuse
Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus
Notice Number: NOT-DA-20-047 https://grants.nih.gov/grants/guide/notice-files/NOT-DA-20-047.html
Applications must be submitted using one of the following targeted funding opportunities:
- PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement – Clinical Trial Optional) is intended to provide funds for NIH grantees applying to expand the scope of their active grant.
- PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) is intended to provide funds for NIH grantees where the work proposed in the supplement is fully within the scope of the ongoing grant.
- The funding instrument, or activity code, will be the same as the parent award.
- Application budgets are generally limited to no more than $100,000 direct costs per year. Should the proposed research require a higher budget, the applicant should consult with the program official assigned to the parent award and include a strong justification for the larger budget in the supplement application. The proposed budget must reflect the actual needs of the proposed project.
- The parent award must be active when the application is submitted. The project and budget periods must be within the currently approved project period for the existing parent award.
- Applications will be accepted on a rolling basis through March 31, 2021 by 5:00 PM local time of the applicant organization. This NOSI expires on April, 1, 2021.
National Institute of General Medical Sciences
Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2
Notice Number: NOT-GM-20-025
NIGMS will accept the submission of applications for Competitive Revisions to active grants to address only the following research areas of interest:
- Incorporation of data related to SARS-CoV-2 into ongoing research efforts to develop predictive models for the spread of SARS-CoV-2 and other related infectious agents (all relevant grants).
- Repurposing or modification of diagnostic tools currently under development to enable rapid detection of SARS-CoV-2 infection (SBIR/STTR grants only).
- Rapid development of potential therapeutic agents for COVID-19 (SBIR/STTR only).
Applications in response to this NOSI must be submitted to PA-18-935 “Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement – Clinical Trial Optional)”, which is intended to provide funds for NIH grantees applying to expand the scope of their active grant. The activity code will be the same as that of the parent award.
- The award project period of the Competitive Revision must not exceed one year.
- Application budgets are limited to no more than the amount of the current parent award, and must reflect the actual needs of the proposed project.
- Competitive revisions to the R15, R21, and R00 may provide support above the established dollar limits for the parent grant award.
- The parent award must be active when the application is submitted.
- Applications will be accepted on a rolling basis from March 25, 2020 to February 5, 2021.
National Science Foundation
- RAPID Research on Coronavirus (COVID-19): https://www.nsf.gov/pubs/2020/nsf20052/nsf20052.pdf
Program Number: NSF 20-052
- NSF is accepting proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge.
- NSF encourages the research community to respond to this challenge through existing funding opportunities.
- It invites researchers to use the Rapid Response Research (RAPID) funding mechanism, which allows NSF to receive and review proposals having a severe urgency with regard to availability of or access to data, facilities or specialized equipment as well as quick-response research on natural or anthropogenic disasters and similar unanticipated events.
- Requests for RAPID proposals may be for up to $200K and up to one year in duration.
- Deadline: Rolling
- Provisioning Advanced Cyberinfrastructure to Further Research on the Coronavirus Disease 2019 (COVID-19)
Program Number: NSF 20-055
Department of Health and Human Services
Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcements (BAA)
- Novel Coronavirus Medical Countermeasures
BAA-18-100-SOL-00003 Amendment 14
COVID-19 response related Areas of Interest includes:
- Diagnostic assay for human coronavirus using existing FDA-cleared platforms
- Point-of-care diagnostic assay for detection of SARS-CoV-2 virus
- Diagnostic assay for detection of COVID-19 disease (SARS-CoV-2 infection)
- COVID-19 Vaccine
- COVID-19 Therapeutics
- Immunomodulators or therapeutics targeting lung repair
- Pre-exposure and post-exposure prophylaxis
- Respiratory protective devices
- Advanced Manufacturing Technologies
Quad Chart and White Paper Deadlines: April 30, 2020; July 31, 2020; October 31, 2020. Proposals submitted following invitation. Budget amounts not specified.
- New Topic under Area of Interest: COVID-19
BARDA Division of Research, Innovation & Ventures (DRIVe)
Six areas of interest:
- Molecular Diagnostic Assay for SARS-CoV-2 virus on existing FDA-cleared platform
- Point-of-Care Diagnostic Assay for detection of SARS-CoV-2 virus
- Diagnostic Assay for detection of COVID-19 disease
- Nonclinical Model Development and Screening for SARS-CoV-2 virus
- COVID-19 Vaccine
- Advanced Manufacturing Technologies
White papers may be submitted until 2023. Proposals submitted following invitation. Budget amounts not specified.